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Abstract: Influenza virus has significant viral diversity, both through antigenic drift and shift, which
makes development of a vaccine challenging. Current influenza vaccines are updated yearly to include strains predicted to circulate in the upcoming influenza season, however this can lead to a
mismatch which reduces vaccine efficacy. Several strategies targeting the most abundant and immunogenic surface protein of influenza, the hemagglutinin (HA) protein, have been explored. These
strategies include stalk-directed, consensus-based, and computationally derived HA immunogens.
In this review, we explore vaccine strategies which utilize novel antigen design of the HA protein
to improve cross-reactive immunity for development of a universal influenza vaccine.
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COBRA; ancestral

Citation: Bullard, B.L.; Weaver, E.A.
Strategies Targeting Hemagglutinin

1. Introduction

as a Universal Influenza Vaccine.

Seasonal influenza epidemics infect between 10–15% of the global population each
year [1]. Symptoms typically last between 5–15 days and include fever, headache, myalgia, and respiratory distress [2]. However, in at-risk patients such as the elderly and immunocompromised, influenza infection can result in severe morbidity and even mortality
[3,4]. In addition to the substantial disease burden from seasonal influenza epidemics,
there is a significant threat to global health from influenza pandemics. Highlighting this,
the 2009 H1N1 swine influenza pandemic infected an estimated 24% of the global population [5].
Influenza virus is a negative-sense, single-stranded RNA viruses with a genome of 8
segments. These segments encode viral proteins including hemagglutinin (HA), neuraminidase (NA), nonstructural 1 (NS1), NS2, matrix 1 (M1), M2, nucleoprotein (NP), nuclear
export protein (NEP), polymerase acid (PA), polymerase basic 1 (PB1) and PB2 [6]. There
is substantial viral diversity in influenza virus, both through antigenic drift from the error-prone RNA polymerase and through antigenic shift from reassortment of the segmented viral genome resulting in novel reassorted viruses [6,7]. The major proteins on the
surface of the virion are HA and NA. Influenza A viruses (IAVs) are classified based on
18 HA subtypes and 11 NA subtypes while influenza B viruses are classified into two
lineages, Yamagata and Victoria. The 18 HA subtypes of IAV are divided into phylogenetic groups 1 and 2 (Figure 1). H1N1, H3N2, and both influenza B lineages currently
circulate in the human population and cause seasonal epidemics. The H2N2 subtype
caused a pandemic in humans in the 1957-1959 influenza seasons, but has, for the most
part, been absent from the human population ever since [8,9]. Importantly, avian influenza strains H5, H7, and H9 subtypes have infected humans from zoonotic transmission
but have shown limited transmission between humans [10]. However, the possibility of
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future mutations which enhance human-to-human transmission led the World Health Organization to recognize these subtypes as potential pandemic viruses [11–13].

Figure 1. Phylogenetic relationship of the influenza A and influenza B hemagglutinin proteins.
Group 1 IAVs (blue) and group 2 IAVs (green) phylogenic groups are indicated. Subtypes which
are known to circulate in humans (or have previously like H2) are circled in red, while subtypes
which infect avian species but are recognized to have significant pandemic potential for zoonotic
transmission are circled in yellow. Representative strains for each HA subtype were aligned using
ClustalW alignment and a maximum-likelihood phylogenetic tree was constructed using
PhyML3.3 on Geneious 11.1.5.

Development of influenza vaccines is challenged by the substantial viral diversity of
influenza virus [14]. The RNA polymerase of influenza virus has no proof-reading activity, which results in high mutation rates and substantial antigenic drift [15]. Therefore,
current seasonal influenza vaccines are updated yearly and rely upon global surveillance
to predict the future circulating seasonal strains [16]. The quadrivalent formulation contains an H1N1, H3N2, and two influenza B viruses, one from the Victoria and Yamagata
lineage [2]. Current seasonal influenzas vaccines are effective at reducing morbidity and
mortality from seasonal influenza infections [17], however vaccine effectiveness estimates
range from 10–60% [16]. Vaccine efficacy relies on the correct prediction and close antigenic match between the chosen vaccine strain and the circulating influenza strain [16]. In
addition, these seasonal vaccines are unlikely to provide protection from novel emergent
pandemic strains (such as the 2009 H1N1 reassorted swine influenza virus).
Many strategies have been explored to increase the cross-reactivity of influenza vaccines, with the goal of developing a universal influenza vaccine. Importantly, HA is the
predominant antigenic protein of influenza viruses and antibodies directed at HA are correlated with protection against influenza virus infection [18,19]. In this review, we explore
vaccine strategies which target the HA protein for development of a universal influenza
vaccine, with a particular focus on novel antigen design of HA to improve cross-reactive
immunity.
2. Hemagglutinin Structure and Function
Hemagglutinin is the most abundant protein on the surface of influenza and functions in viral entry through receptor binding and membrane fusion [6]. HA is also the
predominant antigenic protein and therefore shows the highest rates of adaptive evolution out of all the influenza proteins [20]. Although there are high levels of protein sequence diversity between the subtypes, the HA protein maintains required elements, such
as the cleavage site, secretory signal, fusion domain, transmembrane domain, and cytoplasmic tail as well as common protein structural motifs [21].
HA is a glycoprotein which assembles as a homotrimer on the surface of the virion
(Figure 2) [6]. Each monomer starts initially as a single polypeptide precursor (HA0)
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which is later cleaved into HA1 and HA2 subunits by host proteases. This cleavage is
essential for maturation of the virus to an infectious virion [22]. The HA2 subunit is composed mostly of the stalk region of HA and the C- terminus which has a transmembrane
domain with a cytoplasmic tail that anchors the HA protein to the envelope of the influenza virion. The HA1 subunit contains the signal peptide at the N-terminus and the globular head domain. This globular head domain contains the receptor binding site which
binds sialic acid on the surface of the host cell and facilitates viral entry [7]. Upon internalization of the virion, acidification of the endosome induces a conformational change of
HA, which exposes the N-terminus fusion peptide of the HA2 subunit. The fusion peptide
then facilitates membrane fusion and release of the viral RNA into the cytoplasm of the
host cell [22,23].

Figure 2. Hemagglutinin structure and functional regions. (A) The HA trimer of an H3N2 virus
was downloaded from the Protein Data Bank (PDB: 1HGF; A/X-31) and visualized with PyMOL.
Two monomers are colored in grey while the third monomer shows the head region in green and
the stalk region in blue. An enlarged view of the HA monomer is further colored to show the fusion peptide in red, the long alpha helix (LAH) in orange, and the receptor binding site (RBS) on
the head circled in yellow. (B) A linear schematic of the HA molecular is shown below. The head
domain (green) is on the HA1 subunit, while the stalk domain (blue) spans the C- and N- terminus
of HA1 along with most of HA2. At the N-terminus of HA1 is the signal peptide (SP) while at the
N- terminus of HA2 is the fusion peptide. The transmembrane domain (TMD) and cytoplasmic tail
(CT) are at the C- terminus of HA2.

The globular head of influenza also contains the antigenic sites determined for both
H1 and H3 [7]. Neutralizing antibodies for influenza are typically directed against these
highly antigenic sites on the globular head and interfere with HA binding to sialic acid
[7]. The HA protein of influenza virus has the ability to agglutinate red blood cells. Antiinfluenza virus antibodies which bind to HA and inhibit the hemagglutination activity of
HA are used as a surrogate measure of determining neutralizing antibody titers (HI titers)
[18]. Human serological studies have demonstrated that HI titers of at least 1:40 correlate
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with protection from influenza infection [18,19]. Antibodies directed against the stalk domain of HA have different mechanisms of action, as discussed below, and cannot be measured using an HI assay.
3. Stalk-Directed Strategies
3.1. General Principles of Stalk-Directed Stratgies
One strategy to stimulate broadly reactive antibodies against the large diversity of
HA is to target the more conserved stalk region. The stalk region of HA is occluded on the
surface of the influenza virion and is therefore under less selective pressure from the immune system [24]. Consequently, the stalk region is more conversed as compared to the
globular head of HA, although there is still protein sequence variability within subtypes,
as measured by Shannon entropy (Figure 3). Bioinformatic analysis has shown that the
stalk domain of HA is evolving at a slower rate than the head domain [25]. Protective
efficacy mediated by head-directed antibodies primarily work through direct binding to
HA in order to inhibit viral attachment to sialic acid on host cells, thereby preventing viral
entry. In contrast, stalk-directed antibodies have been proposed to work through alternative mechanisms, such as inhibiting conformational changes at low pH to prevent virus
release from the endosome and preventing maturation of virus by inhibiting cleavage of
HA0 [26]. Additionally, indirect Fc-mediated functions have been reported, such as antibody dependent cell-mediated cytotoxicity (ADCC) and triggering of complement-dependent cytotoxicity (CDC; reviewed in [26]). This has been further supported by results
indicating that stalk antibodies require Fc-mediated interactions for in vivo efficacy
[27,28]. While antibodies directed to the head of HA are typically measured by HI titer,
the non-classical effector functions of stalk-directed antibodies require alternative methods to measure antibody titers, such as ELISA or ADCC reporter assay.

Figure 3. Conservation of the stalk of hemagglutinin. (A) The conservation scores of the pre-pandemic seasonal H1N1
(sH1N1) influenza viruses were calculated using the ConSurf server (https://consurf.tau.ac.il/) and visualized using
PyMOL. Protein sequence variability was determined with the Shannon entropy server (https://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy_one.html) using ClustalW aligned HA protein sequences from pre-pandemic seasonal
H1N1 (B; sH1N1), pandemic H1N1 (C; pH1N1), and H3N2 (D). All human isolates with complete HA protein sequences
(duplicates and lab strains excluded) were downloaded from the Influenza Research Database, resulting in 962 strains for
sH1N1 (strains up to 2009), 7423 strains for pH1N1 (strains during and after the 2009 pandemic), and 9043 strains for
H3N2. The stalk, head, and fusion peptide are colored in blue, green, and red, respectively.
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Stalk-directed antibodies have shown cross-reactivity within subtypes and between
multiple subtypes within a group and even between group 1 and 2 viruses. A comprehensive list of stalk-directed antibodies discovered have been previously described [29]. Researchers have explored many vaccination strategies to induce these stalk-directed antibodies (Figure 4), however induction of antibodies against the immunosubdominant stalk
domain remains challenging in the presence of the immunodominant head domain. Efforts to overcome this challenge include development of “headless” HA constructs, hyperglycosylation of the head, expression of just the long alpha helix (LAH) domain of the
stalk, and development of chimeric and mosaic HAs.

Figure 4. Vaccine strategies to increase stalk-directed immunity. Strategies used to induce stalk-directed immunity, such
as hyperglycosylation of the HA [30–32], development of a headless HA [33–47], expression of the LAH fragment alone
[48–50], and chimeric [51–62] and mosaic [63,64] HA proteins, have been illustrated and briefly described here.

3.2. Design of Stalk-Directed Vaccines
3.2.1. Headless HA Constructs
One strategy to increase antibodies directed to the immunosubdominant stalk region
is through removal of the immunodominant head domain creating a “headless” HA. Importantly, HA is a metastable protein which undergoes extensive conformation changes
at low pH during the infection cycle of influenza [35]. Removal of the HA1 head domain
destabilizes the HA2 structure resulting in loss of antibodies targeting the native conformational epitopes. This was demonstrated in the first reported experiment developing a
headless HA in 1983, which removed the HA1 domain of HA through chemical treatment
with acid and a reducing agent [33]. However, this vaccine did not show protective efficacy, likely due to denaturation of conformational stalk epitopes. Other efforts to express
only the HA2 subunit in systems such as recombinant baculovirus or E. coli have resulted
in stalk antigens which lack the native confirmation and are not recognized by neutralizing anti-stalk antibodies [34–36].
Multiple strategies have since been explored to express the HA stalk region in a native-like, neutral-pH conformation. One group stabilized the stalk through inserted specific mutations intended to destabilize the low pH conformation of HA2 thereby pushing
the protein to a neutral pH conformation. This approach has been applied to both H1 and
H3 proteins [37,38]. The stabilized HA2 protein was expressed in E. coli and folded into a
neutral-pH conformation. However, mice vaccinated twice with the stabilized H1 stalk
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protein were protected from mortality, but not morbidity (~18% weight loss), after challenge with a lethal homologous strain [38]. Another group stabilized the H1 or H3 HA2
domain through inclusion of stabilizing linker peptides and vaccinated mice with two
doses of DNA protein expression plasmids followed by a virus-like particle (VLP) formulation [65]. Vaccination with this headless HA completely protected mice from a challenge
with a homologous virus strain (~5% weight loss) and induced greater in vitro heterosubtypic cross-reactive antibodies.
Other groups have aimed to express stable headless HA in a trimer conformation
either as a soluble protein [39–43] or on the surface of virus-like particles (VLP) [44] or
nanoparticles [45–47]. One group developed a soluble “mini-HA” H1 stalk trimer through
multiple structure-based mutations [39]. Three immunizations with this “mini-HA” H1
stalk completely protected mice from weight loss and death after lethal challenge with
either heterologous H1 or heterosubtypic H5 influenza virus. Sera from these mice had
both neutralizing and ADCC effector functions. Another group stabilized an H1 stalk trimer through six iterative cycles of structure-based mutations and displayed the stalk on
the surface of a nanoparticle [45]. Three immunizations with these nanoparticles completely protected mice from heterosubtypic challenge with H5 influenza virus but showed
only partial protection in ferrets. Vaccinated mice and ferrets showed strong in vitro antibody binding against group 1 subtypes H1, H2, H5, and H9 with some weak responses to
group 2 subtypes H3 and H7. However, there was limited neutralizing antibodies detected against heterosubtypic strains, indicating that protection is likely mediated by other
stalk antibody-dependent mechanisms, such as ADCC or CDC. This stabilized H1 trimer
nanoparticle vaccine has since progressed into a phase I clinical trial with 52 participants
and is expected to conclude December 2021 (NCT03814720).
3.2.2. Chimeric HA
To overcome the instability of headless stalk constructs while still boosting stalk-directed antibodies, a chimeric HA protein prime/boost strategy was developed. In this
strategy, multiple sequential immunizations of chimeric HA proteins containing the same
stalk region, but ‘exotic’ HA heads, results in a boosting of stalk-directed immunity. A
major benefit of this approach is that the full-length HA is expressed, thereby presenting
the stalk domain in the correct conformation. This chimeric strategy has been explored for
use as H1 [51–58], H3 [59], and influenza B virus vaccines [60].
To boost stalk immunity against H1, mice were sequentially vaccinated with three
doses of chimeric HA which all had the same H1 stalk but head regions from H9, H6, or
H5 [52]. Mice were completely protected from lethal challenge with three homosubtypic
H1 viruses. The authors also explored heterosubtypic protection and, to rule out the contribution of head-directed antibodies, immunized mice with a similar chimeric prime
boost strategy but replaced the head domain of the corresponding challenge strain with a
H1 head instead. Vaccination with this strategy completely protected mice from death
after lethal heterosubtypic challenge with H5, H6, and H3 viruses, however weight loss
data is not reported, although the authors state that only minimal weight loss was observed. Efficacy of this vaccine was demonstrated in a preclinical ferret model, where vaccination with the chimeric prime/boost strategy reduced viral nasal wash titers after challenge with a heterologous H1 virus [51] and heterosubtypic H6 virus [57], and demonstrated durability of protection against homologous H1 challenge up to 1 year after immunization [58]. Delivery of the H1 chimeric antigens has been explored utilizing multiple
vaccine platforms, including a DNA prime with recombinant protein boosts [52], recombinant live-attenuated virus and inactivated virus [55–57], vesicular stomatitis virus (VSV)
viral vectors [51,53], and adenovirus vectors [51].
Importantly, results from a phase I clinical trial of 65 participants have been reported
[61,62]. Participants received two immunizations with different combinations of chimeric
HA live-attenuated virus, inactivated virus, or inactivated virus plus adjuvant vaccines.
Vaccination was found to be safe and to successfully induce anti-stalk H1 antibodies. The
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best results were observed in participants who received two doses of chimeric HA inactivated adjuvanted virus, in which anti-stalk antibodies persisted at ~4-fold above baseline
for up to 1.5 years. Mice who received a passive transfer of sera from vaccinated participants showed a trend towards reduced weight loss as compared to mice who received
sera from the placebo group after challenge with recombinant H1 stalk virus. This clinical
trial supports the ability of this chimeric HA vaccine strategy to induce anti-stalk antibodies in humans, however clinical trials are needed to demonstrate the efficacy of these stalkdirected antibodies in protecting humans from infection. While the most progress has
been made using the H1 subtype vaccine, this strategy has also been explored for H3 [59]
and influenza B [60] with promising results. Combining these candidate immunogens into
a multivalent vaccine has not yet been explored.
3.2.3. Hyperglycosylated HA
Another strategy to increase stalk-specific responses is to hyperglycosylate the HA1
head region in order to ‘mask’ the immunodominant epitopes, thereby directing the response to the stalk [30]. Three immunizations of mice with a hyperglycosylated H1 protein
induced stronger anti-stalk antibodies against the homologous H1 stalks than a wild type
HA [32].The hyperglycosylated H1 also induced greater cross-reactive antibodies to two
heterologous H1 viruses and a heterosubtypic H5 virus. Hyperglycosylated H1 vaccinated mice were protected from mortality, but not morbidity (~10% weight loss), after
challenge of mice with a chimeric H1 stalk virus.
This strategy has also been applied to target the H5 stalk [30,31]. Immunization of
mice with a replication-defective adenovirus vector expressing a hyperglycosylated H5
clade 1 HA and boosted with recombinant protein induced greater cross-reactive antibodies against three heterologous clade 2 viruses as compared to a wildtype virus [31]. While
this vaccination induced homosubtypic antibodies against H5, it did not result in significant antibody responses to other group 1 viruses (H1, H3, H9). Vaccination with hyperglycosylated H5 protected mice from mortality, but not morbidity (~13% weight loss), after challenge with a heterologous clade 2 virus, with no significant difference in weight
loss observed between the hyperglycosylated H5 or wildtype HA vaccine. Therefore,
while hyperglycosylation of the HA1 head does appear to increase anti-stalk antibodies
as compared to the wildtype HA, vaccination does not protect mice from severe influenza
morbidity, even against a homosubtypic challenge.
3.2.4.“Mosaic” HA
Another strategy to silence the immunodominance of the HA1 head subunit and direct the immunity to the stalk region involves substitution of the immunodominant antigenic sites on the HA1 head, yielding a “mosaic” HA1 region. One strategy silenced the
immunodominant antigenic sites of the H3 head by replacing them with amino acid sequences from an avian HA protein (H10 or H14) [63]. Mice vaccinated with this recombinant mosaic H3 protein induced more H3 stalk-directed antibodies than the commercial
inactivated seasonal vaccine. Passive transfer of sera from mice vaccinated with this adjuvanted mosaic recombinant H3 protein protected mice from death after lethal challenge
with two heterologous H3 viruses, however mice still experienced severe weight loss
(~20% weight loss).
This strategy was also applied to an influenza B vaccine, where immunodominant
antigenic sites of an influenza B Yamagata lineage virus was replaced with amino acid
sequences from H5, H8, H11, or H13 [64]. Vaccination of mice with a DNA prime and two
recombinant protein boosts of this mosaic head protein resulted in complete protection
from weight loss and death after challenge with a lethal Yamagata and Victoria strain.
Antibodies induced after vaccination with the mosaic HA showed cross-reactive ELISA
antibodies against three Yamagata lineage viruses and three Victoria lineage viruses. No
HI antibodies or neutralizing antibodies were detected, but there were antibodies detected
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through an ADCC reporter assay, indicating that efficacy of this mosaic vaccine was conferred primarily through Fc-mediated effector functions.
3.2.5. LAH Fragment
In an attempt to overcome the challenges with expression of a stable headless stalk
and the immunodominance of the HA1 head, some strategies instead target only a small
portion of the stalk region, such as the long alpha helix (LAH) or fusion peptide. One
strategy conjugated the LAH of H3 to a carrier protein [48]. Two immunizations of mice
with this LAH vaccine showed complete protection from death after a lethal challenge
with heterologous H3 virus, however mice still exhibited severe weight loss (~15% weight
loss). This LAH vaccine only partially protected from death after lethal heterosubtypic H5
challenge and did not protect against lethal heterosubtypic H1 challenge. There was similar findings by another group, which expressed the LAH and fusion peptide from H5 in
E. coli and refolded the protein from inclusion bodies [50]. Mice immunized with this protein were completely protected from weight loss and death after challenge with the homologous H5 virus but only partially protected from death after challenge with a heterologous H5 virus or a heterosubtypic H1 virus. Additionally, vaccination of mice with the
LAH of H1 expressed on a hepatitis B virus-like particle (VLP) demonstrated complete
protection from mortality after challenge with a lethal homologous H1 virus, heterologous
H1 virus, and heterosubtypic H9 virus, although mice still showed severe weight loss of
~15%, 7%, and 19%, respectively [49]. Therefore, although vaccination with the LAH does
increase heterosubtypic protection, the morbidity after challenge is often still severe.
3.3. Challenges Facing Stalk-Directed Strategies
Although these stalk-directed vaccination strategies do induce greater cross-reactive
immunity, the weak immunogenic nature of the stalk domain necessitates as many as
three immunizations to induce this immunity. In addition, animals still exhibit severe
morbidity even after challenge with homosubtypic strains, often losing more than 10% of
their initial starting weight, although they are protected from mortality. This is likely due
to the Fc-mediated mechanism of action found to be a large contributor to protection in
many stalk-directed strategies, as these mechanisms are not neutralizing but rather contribute to viral clearance after infection [26]. This indicates that although the breadth of
reactivity is increased with these stalk-directed approaches, the robustness of the protection is diminished [66].
Additionally, although the stalk region of HA is more conserved than the head region, there is still variability within subtypes (Figure 4) and the stalk region is still susceptible to selective pressures from the immune system [67]. This is highlighted by the discovery that pre-existing stalk-directed antibody titers select for a stalk-antibody escape
mutant after human influenza challenge [67]. Furthermore, while these stalk-directed antibodies do confer protection from mortality in animal models, there is still conflicting
literature about the efficacy of these anti-stalk antibodies in humans. One study utilizing
a human household transmission experimental design found a correlation between HA
stalk-directed antibodies and protection from infection [68]. In contrast, another study using human samples demonstrated that there was no significant correlation between stalk
antibodies and protection from influenza virus infection after adjustment for head-specific
antibodies [69]. In addition, a phase II trial examining the therapeutic efficacy of a monoclonal stalk-directed antibody showed no clinically significant effect on influenza disease
[70]. These conflicting results draw into question the protective efficacy of these anti-stalk
antibodies in humans.
4. Consensus-Based Strategies
4.1. General Principles of Consensus-Based Stratgies
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Unlike stalk-directed strategies, consensus-based approaches target the full-length
HA protein and aim to design an HA protein which is broadly representative of the diverse HA population. These HA genes are computationally designed and therefore are
synthetic in nature. Although the central concept behind consensus-based strategies is
similar, many different approaches have been developed (Figure 5). Importantly, unlike
stalk-directed strategies, consensus-based approaches typically induce HI antibodies directed against the head region of HA, which is generally accepted as a correlate of protection against influenza infection in humans [29,71]. Consensus-based approaches are typically developed for a single subtype of influenza, with the intention of expanding the approach to multiple subtypes and combining the vaccine constructs into a single multivalent vaccine.

Figure 5. Consensus-based antigen design strategies. Consensus strategies are designed by aligning the target HA protein
sequence population and determining the most common amino acid at each position. ‘Consensus’ immunogens are designed using all the HA protein sequences from the phylogenetic tree. ‘Micro-consensus’ immunogens are created by
taking a consensus of each major branch of the phylogenetic tree and delivering the immunogens as a cocktail. ‘Centralized’ immunogens aim to reduce sampling bias by taking a representative wildtype HA from each branch of the phylogenetic tree and designing a consensus of those HA protein sequences. ‘COBRA’ immunogens also aim to reduce sampling
bias and use multiple rounds of consensus building.

4.2. Design of Consensus-Based Vaccines
4.2.1. Consensus Hemagglutinins
Consensus HA genes are constructed by taking the most common amino acid at each
position of the HA after aligning a protein sequence population. A consensus strategy has
been explored by multiple groups to target highly pathogenic avian influenza (HPAI)
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H5N1 virus [72–75], which poses a substantial pandemic threat. In addition, H5N1 has
high viral diversity, with multiple clades and subclades [76]. Two immunizations of mice
with a consensus H5 gene expressed in a DNA plasmid induced cross-reactive antibodies
against multiple different H5 viruses from two clades [72]. Vaccination conferred complete protection from morbidity and mortality after challenge with two H5 clades but only
partial protection after challenge with more distantly related H5 viruses. Additionally, a
consensus H5 protein expressed in VLPs completely protected chickens from lethal challenge with two H5 viruses from separate clades [74]. Importantly, these consensus immunogens are designed using all H5 protein sequences in the database, which can lead to
geographical sampling/sequence bias and result in a consensus HA that might not accurately reflect the HA diversity of the population.
4.2.2. Micro-Consensus Hemagglutinin
While other consensus designs develop a single consensus HA per subtype, Elliott et
al. (2018) explored the efficacy of four micro-consensus immunogens to improve crossreactivity to the H3 subtype [77]. These four micro-consensus genes were expressed in a
DNA plasmid and administered twice as cocktail. Vaccination of mice with this cocktail
induced strong antibody responses against 8 strains circulating between 1968 and 2014 as
measured by ELISA and induced significant HA-specific cellular immunity. Vaccination
also protected mice from lethal challenge with two H3N2 strains, with 5–10% weight loss.
Importantly, this study finds that a cocktail of consensus immunogens might improve
cross-reactivity of highly diverse HA populations, such as the H3 subtype.
4.2.3. Centralized Hemagglutinins
Another consensus-based strategy aims to develop a synthetic HA which localizes to
the central node of the phylogenetic tree, thereby minimizing genetic and antigenic differences of unmatched strains. An important limitation to consensus strategy described
above is the threat of sampling bias leading to generation of a synthetic HA gene which
does not accurately represent the diversity of the population and is biased towards an
overrepresented geographical location. Weaver et al. (2011) overcame this by developing
a centralized H1 gene using selected representative wildtype HA protein sequences from
each major branch of the phylogenetic tree and designing a consensus of those sequences
[78]. In this way, each branch is equally represented to prevent sampling/sequencing bias
and, as a result, this synthetic HA gene localizes to the central node of the tree. This centralized H1 gene was expressed in a replication-defective adenovirus vector and vaccination of mice resulted in better cross-protection against three H1 strains as compared to
mismatched wild type HAs or traditional influenza vaccines after lethal influenza challenge [78]. This strategy was then applied to develop H3 and H5 centralized genes which
also demonstrated improved homosubtypic cross-protection [79]. Importantly, a combination of H1, H2, H3, and H5 centralized genes into a single multivalent vaccine did not
diminish the increased cross-reactive protection [80]. A single immunization at the high
dose of this multivalent formulation demonstrated complete protection from morbidity
and mortality after lethal challenge with three H1 strains, three H5 strains, and one H3
strain with partial cross-protection against another two H3 strains. This validates the approach of designing multiple subtype-specific broadly reactive HA immunogens which
can then be combined into one multivalent vaccine without reduction in cross-reactivity
or interference between immunogens.
4.2.4. COBRA Hemagglutinins
Like the centralized HA design, another antigen design method called computationally optimized broadly cross-reactive antigen (COBRA) aims to minimize sampling/sequencing bias in the target population. The COBRA strategy achieves this through multiple rounds of consensus generation. A COBRA vaccine strategy has been developed and
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tested for H1 [81–85], H2 [86], H3 [87,88], H5 [89–96], and swine H1 [97]. These COBRA
immunogens have primarily been expressed using a VLP platform but have also been
explored using ferritin nanoparticles [84] and recombinant live influenza virus [83]. This
strategy was first explored as a H5 vaccine targeting only clade 2 and was tested in mice,
ferrets [89,90], chickens [95], and non-human primates (NHP) [91]. Vaccination of NHP
induced cross-reactive HI antibody titers against multiple clade 2 viruses and against a
clade 1 and 7 influenza virus. This strategy was then expanded to target the entirety of the
H5 diversity by using a cocktail of three COBRA immunogens designed for human clade
2, human and avian clade 2, and all H5 clades [92]. Vaccination of mice with two doses of
this cocktail induced protective HI titers to twenty-five H5 viruses from eleven H5
clades/subclades, however cross-protection was only evaluated after immunization with
individual COBRA immunogens and was not evaluated after vaccination with the cocktail.
The COBRA strategy was also evaluated for protection against seasonal and pandemic H1 strains [82]. Nine different COBRA H1 immunogens were designed and four
immunogens were selected for further investigation based on their increased cross-reactivate HI titer and protection. These immunogens were evaluated in sequential
prime/boost immunizations strategies or as a heterologous cocktail. Results found that the
broadest HI titers were induced by a combination of COBRA immunogens designed using
both seasonal and pandemic H1 strains, with a trivalent cocktail demonstrating protective
HI titers to ten of the fifteen H1 strains [82]. This increased HI cross-reactivity extended to
a pre-immune ferret model [81]. However, cross-protection was only evaluated against a
single pandemic strain.
A similar strategy was used for the H3 subtype, in which seventeen CORBA immunogens were designed with only four of these immunogens showing promising HI titers
in mice [87]. The four immunogenic H3 COBRA immunogens were further explored in a
ferret model [88]. Although vaccination of naïve mice showed promising cross-reactivity,
vaccination of naïve ferrets showed low HI titers and narrow cross-reactivity, with the
most cross-reactive immunogen showing protective HI titers to only six of the thirteen H3
strains. In contrast, ferrets that were pre-immune to a historical H3 strain prior to vaccination showed increased cross-reactive HI titers against the entire panel of 13 viruses after
vaccination with COBRA immunogens as compared to vaccination with a wildtype HA.
This led the authors theorize that, although there was limited efficacy in naïve ferret, the
COBRA immunogens were more effective than wildtype HA at recalling broad cross-reactive memory B cells from previous influenza infection. Therefore, while this H3 COBRA
vaccine might boost cross-reactive immunity in pre-immune adults, more research needs
to be performed to examine potential efficacy in naïve populations, such as children. In
addition, although the COBRA strategy has been explored for multiple influenza subtypes
individually, COBRA has not yet been explored as a multivalent formulation targeting
multiple subtypes.
4.3. Challenges Facing Consensus-Based Approaches
Consensus-based approaches target the full-length HA protein and therefore typically induce antibodies directed against the variable head region. For this reason, these
vaccines are subtype-specific and do not show the cross-reactivity between subtypes of
the same phylogenetic group, as is observed in stalk-directed strategies discussed above.
However, antibodies induced by these consensus-based approaches have improved crossreactivity within a subtype and often demonstrate HI activity which is a correlate of protection against influenza infection in humans [29,71]. Therefore, what these approaches
lack in breadth of immunity between subtypes, they make up for in robustness of protection within subtypes.
Consensus-based influenza vaccines based on the HA protein are a more recent concept than the stalk-directed strategies and therefore have not progressed to human clinical
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trials yet. In addition, unlike stalk-based strategies, little work has been performed to evaluate the potential for escape mutants from pre-existing immunity induced by consensus
vaccines. The subtype-specific immunity induced by consensus vaccines will necessitate
a multivalent cocktail of HA immunogens to protect against the multiple subtypes currently circulating in humans. Further work to demonstrate that a multivalent vaccine containing many immunodominant antigenic sites from different subtypes does not reduce
efficacy through interference. However, the centralized HA approach has shown that vaccination of mice with a quadrivalent vaccine showed no reduction in efficacy, indicating
that this a promising strategy to induce a robust protective immune response against multiple subtypes relevant to human health.
5. Computational Algorithms for Immunogen Design
5.1. General Prinicples of Computational Algorithm Approaches
Similar to consensus-based strategies, approaches using computational algorithms
target the full-length HA protein and aim to develop a synthetic HA which is broadly
representative of the diverse influenza virus population. However, these strategies use
complex computational algorithms in order to logically design a broadly reactive HA immunogen in silico.
5.2. Design of Computional Algorithm Vaccines
5.2.1. Ancestral Hemagglutinin
A phylogenetic algorithm called ANCESCON reconstructs the ancestral HA gene using marginal and joint reconstruction methods [98]. Ducatez et al. (2011) used this algorithm to develop a cross-reactive H5 vaccine, in which the putative ancestral gene for
avian H5 was predicted and expressed in a recombinant, replication-competent influenza
virus [76]. Vaccination of ferrets with the ancestral gene induced in vitro cross-reactivity
to five H5 clades and protected ferrets from death after lethal challenge with three H5
viruses from two clades. However, a wild type H5 reference virus also showed similar
levels of cross-reactive immunity and protection. Crucially, this study demonstrated a
proof-of-concept that synthetic HA genes could be expressed using an inactivated recombinant virus which is a currently licensed influenza vaccine platform.
This ANCESON algorithm was also used to develop an ancestral avian H9 immunogen that was expressed in a Modified Vaccinia Ankara (MVA) vector [99]. Intramuscular
vaccination of chickens resulted in poor cross-reactive HI titers, with measurable titers
against only one of the ten avian influenza virus strains and did not reduce viral shedding
after challenge. Therefore, although reconstruction of the ancestral HA gene aids in our
understanding of the evolutionary processes underlying the HA protein, the improved
cross-reactive efficacy of these immunogens has yet to be demonstrated. In addition, phylogenetic uncertainty from long branches and genetic drift might weaken this approach
[100].
5.2.2. Mosaic Algorithm
Another algorithm, called the Mosaic Vaccine Designer tool, aims to maximize the
potential epitope coverage of the target viral population [101,102]. A graphic visualization
of the algorithm approach has been previously described [102]. Simplified, full-length HA
protein sequences undergo repeated rounds of in silico recombination and the recombinant HA protein which has the best epitope coverage of the original target population is
selected as a single mosaic HA immunogen. Crucially, this algorithm results in a mosaic
immunogen that typically has better epitope coverage than a consensus strategy. Mosaic
HA immunogens have been designed for H5 [103–106] and H1 [107]. A mosaic H5 expressed in MVA completely protected mice from morbidity and mortality after lethal virus challenges with four H5 viruses from three clades and provided protection from mor-
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tality, but not morbidity (~10% weight loss), after challenge with a heterosubtypic H1 virus [103]. T-cell depletion and passive transfer studies found that homosubtypic protection is primarily from cross-reactive antibodies, while the heterosubtypic protection to H1
is from cross-reactive CD8+ cells [104]. Vaccination with the mosaic H5 immunogens was
also shown to increase early viral clearance in the lungs of NHP after challenge with H1
virus [105] and eliminate viral shedding in chicks after challenge with H5 virus [106]. This
mosaic algorithm was also used to design a H1 mosaic immunogen which was expressed
in a replication-defective adenovirus vector [107]. Vaccination of mice showed increased
cross-reactive ELISA antibodies and T-cell responses to a panel of four H1 viruses as compared to mismatched wild type HA immunogens. In addition, the high dose immunization of mosaic H1 provided complete protection from morbidity and mortality after challenge with three H1 viruses. These studies demonstrate the efficacy of a computational
algorithm which creates a vaccine antigen optimized to include the most common
epitopes from the target population.
5.2.3. Epigraph Algorithm
Similar to the mosaic algorithm, the epigraph algorithm aims to design vaccine antigens which contain the most common epitopes from the target population, thereby representing the diversity of HA protein sequences and biasing towards antigen recognition by
the immune system [108,109]. The epigraph algorithm uses a faster graph-based approach
and creates a user-defined cocktail of computationally designed HA proteins. A graphic
visualization of the algorithm approach has been previously described [108]. The epigraph algorithm has been used to design a swine H3 immunogen, with the goal of reducing the pandemic potential of H3 from zoonotic transmission events [110]. This epigraph
HA was expressed in a replication-defective Adenovirus vector and vaccination of mice
induced increased cross-reactive antibodies as compared a wildtype HA or the commercial vaccine, with protective HI titers to fourteen of the twenty diverse swine H3 influenza
virus strains. Importantly, this improved cross-reactive antibody response induced by the
swine H3 Epigraph immunogens was also seen in swine, the target animal of this vaccine.
Of interest, this swine H3 epigraph vaccine also induced cross-reactive antibodies with
human H3 strains, suggesting the possibility of reduced reverse zoonotic events. Challenge studies in mice showed greater cross-protective efficacy after challenge with three
swine H3 strains, however challenge studies in swine are needed to demonstrate this protective efficacy in the target animal. The broad cross-reactive immunity induced by this
vaccine demonstrated the efficacy of a cocktail of computationally designed HA immunogens.
5.3. Challenges Facing Computational Algorithm Approaches
Computational algorithm approaches face many similar challenges as the consensusbased approaches, such as the possibility of escape mutants and subtype specific immunity induced by vaccination. Computational power continues to progress, and consequently computational algorithm approaches are the most recent advances in novel antigen design for influenza vaccines. Therefore, these approaches are still in their infancy
and further research is needed to demonstrate their efficacy. However, the promising results discussed above lend support towards a computational algorithm improving crossreactive immunity against the HA protein of influenza.
6. Perspectives
In this review we have explored multiple novel immunogen design strategies which
aim to improve cross-reactive immunity against the HA protein for the development a
universal influenza vaccine. These strategies target either the more conserved stalk region
of HA or aim to design a synthetic full-length HA which is representative of the influenza
viral diversity, either through a consensus-based approach or computational algorithms.
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Some of these strategies have been explored in depth, with headless stalk constructs and
chimeric HA progressing to human clinical trials. Other strategies are more recently developed but still present a promising approach towards a universal influenza vaccine.
Importantly, the strategies presented here all utilize different vaccine platforms, from viral vectors, to purified recombinant protein, to VLPs. The vaccine platform and immunization strategy can have a profound effect on the cross-reactive immunity induced by
vaccination, which therefore makes these strategies difficult to compare head-to-head.
However, in general, stalk-directed strategies induce antibodies which cross-react with
multiple subtypes within a phylogenetic group and protect from mortality, but still result
in significant morbidity after challenge. In contrast, full-length synthetic HA vaccines induce only subtype-specific immunity, but protect mice from both morbidity and mortality. This is likely due to the different mechanisms of action of stalk-directed versus headdirected antibodies. Therefore, a tradeoff is made in which increased cross-reactivity leads
to a reduction in the robustness of protection. Overall, many of these novel antigen design
strategies have shown promise in improving the cross-reactive immunity to influenza and
should be further explored as a universal influenza vaccine.
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